Mitchell Cairo
Pediatric Hematology-Oncology · Hawthorne, NYNPI 1669446399
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 29.9% of the total. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 835 payments — averaging $1326.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$332K
- Gilead$201K
- Servier Pharmaceuticals LLC$168K
- Amgen$163K
- Sanofi$50K
- E.r. Squibb & Sons, L.L.C.$50K
- plus $145K from 14 others
Across 147 payments — averaging $59,190 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$5.5M
- Merck$1M
- Servier Pharmaceuticals LLC$492K
- Regeneron$468K
- Spectrum Pharmaceuticals Inc.$387K
- Celularity Inc.$240K
- plus $576K from 10 others
What the payments were for
- Consulting fees$387,06535%
- Speaking & faculty fees$595,77754%
- Grants$15,0001%
- Travel & lodging$94,5729%
- Food & beverage$15,4321%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 287 | $331,599 |
| Gilead(2 entities) | 33 | $200,545 |
| Servier Pharmaceuticals LLC | 224 | $167,773 |
| Amgen | 149 | $162,591 |
| Sanofi | 24 | $49,963 |
| E.r. Squibb & Sons, L.L.C. | 5 | $49,950 |
| Sobi, Inc | 70 | $48,644 |
| Pfizer | 6 | $32,625 |
| Celularity Inc. | 3 | $15,069 |
| Omeros Corporation | 4 | $12,899 |
| Novartis | 3 | $10,463 |
| Sanofi US Services Inc. | 1 | $7,500 |
| Astrazeneca UK Limited | 1 | $6,850 |
| AstraZeneca | 4 | $4,805 |
| Merck | 16 | $4,142 |
| La Jolla Pharmaceutical Company | 1 | $2,100 |
| Syndax Pharmaceuticals, Inc. | 1 | $135 |
| Kadmon Pharmaceuticals LLC | 1 | $100 |
| Mesoblast, Inc. | 1 | $99 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,107,864 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in Hawthorne
- Claudio SandovalHawthorne$54K
- Oya TugalHawthorne$49K
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- Mary SugrueGarden City$253K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- Jennifer DavilaBronx$126K
- Beverly SchaeferBuffalo$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.